Background. Rimonabant treatment, examined in Phase 3 trials, showed improvement of cardiovascular risk factors in obese patients.
Introduction
Obesity is associated with major risk factors (e.g. hypertension, dyslipidaemia and insulin resistance) for cardiovascular disease (CVD) and diabetes mellitus type 2 and is an important cause of death worldwide. [1] [2] [3] [4] [5] While lifestyle intervention is the cornerstone of therapy, it seems that pharmacotherapy, aiming to reduce these cardiovascular and metabolic risk profiles, is often needed. Prevention centred on controlling these risk factors has led to multiple classes of drugs, such as antihypertensives, antidiabetics, cholesterol lowering and anti-obesity drugs. 6 With the discovery of the endocannabinoid system, a new target for multiple risk factor management appeared to be found. The Rimonabant in Obesity (RIO), Phase 3 trials, showed spectacular improvements in waist circumference, high-density lipoprotein (HDL) cholesterol, triglycerides and insulin resistance. [7] [8] [9] [10] Even though the cannabinoid-1 (CB1) receptor blocker, rimonabant, has been withdrawn from the market due to the psychiatric side effects, the obesity and diabetes pandemic urge the development of new agents for risk management.
This study assessed the effectiveness (the effect on cardiovascular risk factors and quality of life) of rimonabant plus lifestyle counselling in daily practice. The hypothesis was that the effectiveness in Phase 4 would be smaller than the efficacy in Phase 3. Phase 3 trials are usually designed to demonstrate the potential advantages, as well as possible side effects, of new therapy and are conducted under standardized conditions, but mostly differ from the reality in daily life. 11 Phase 4 trials occur after the approval and release of a new drug and are designed to provide additional information, including the drug's risks, benefits and optimal use. In daily practice, people may have co-morbidity, may use other treatments and may be less compliant to use a specific drug than in controlled studies. These differences in patient selection and treatment conditions may affect both the effectiveness and risks of a drug.
The CARDIO-REDUSE study started before the market release of rimonabant. Shortly after market introduction and in the finishing period of this Phase 4 trial, rimonabant was suspended of all markets due to psychiatric side effects. 12 Therefore, this study is unique in its kind because it presents exclusive real life data on the effectiveness of rimonabant. Lessons learnt in daily practice might help set a new agenda for further development of pharmacotherapy on cardiovascular and metabolic risk factor management.
Methods

Study design
This double-blind, randomized placebo-controlled trial, which compared rimonabant with a placebo, was conducted between November 2006 and December 2008 and was part of a large study, described in the controlled trials register (ISRCTN63367873). The CARDIO-REDUSE study was approved by the Medical Ethics Committee of the Maastricht University and the Central Committee on Research Involving Human Subjects (CCMO), the Netherlands (MEC 06-3-050).
Recruitment
Practices were recruited from the region of Limburg, and study information was sent to 29 general practices. Then, the GPs were contacted personally by telephone and asked for their participation in this study. Overall, 22 practices, of those contacted, decided to participate in this study. Most of these practices (n = 14) were associated with the CAPHRI School for Public Health and Primary Care via the Registration Network General Practices (RNH). 13 Apart from this recruitment via RNH, the CARDIO-REDUSE team also recruited participants via advertisements in local newspapers to reach the estimated sample size. By using the International Classification of Primary Care codes for diabetes type II and overweight/obesity in the medical computer system of the general practices, a first selection of potential participants was made. To select a patient population representative of real life circumstances, the inclusion and exclusion criteria were based on the special warnings in the rimonabant leaflet ( Table 1) . Since there was no information available for the medication use by children and elderly, it was unethical to include these patients in this randomized controlled trial (RCT). Therefore, the age range of 18 through 75 years old was made.
Since randomization was performed on patient level, only one subject per household was allowed. When approved by the GP, eligible patients received an invitation letter and a response form. The nurse practitioner invited the positive responders for a screening visit and informed them about the study. If they signed the informed consent form and fulfilled all criteria, participation could start.
Interventions
During the study year, there were five visits: at screening, 0 months (start), 3 months, 6 months and 12 months (follow-up). All patients received the blinded study medication [half rimonabant 20 mg and half placebo (indistinguishable in appearance, smell and taste)] and lifestyle counselling. The counselling sessions were provided by a nurse practitioner conform the NHG guidelines (Dutch college of GPs). 5, 14 There was no strict diet, patients were able to chose their own lifestyle changes. During the treatment year, these personal goals were registered and monitored. Co-medication was allowed, with the exception of the medication listed in the rimonabant leaflet under precautions for use (Table 1) .
Randomization
The randomization in this double-blind placebocontrolled trial was performed on patient level (block design). The manufacturer packed 50 blocks with each six medication kits and the investigators brought these to the different GPs. One block contained visual identical kits, three kits with rimonabant and three kits with placebo. Each kit contained 12 wallets with 36 tablets. After the participants signed the patient consent, they received their first wallet of double-blind medication. This procedure gave the advantage of assigning approximately equal numbers of patients in each general practice to each treatment. The sealed randomization list codes were kept by the coordinating investigator.
If knowledge of the study medication was necessary for the treatment of serious adverse events (SAEs), the coordinating investigator was allowed to break this randomization code. None of the randomization list codes were broken due to a SAE before the end of this study.
Outcome measures
The outcomes of this study were measured at screening, 3 months, 6 months and 12 months by the nurse practitioners. The outcome measures included the separate cardiovascular risk factors, i.e. body weight, plasma glucose, HbA1c, lipid profile, blood pressure and the main outcome waist circumference. Subsequently, the variables sex, ethnicity, smoking, age at diagnosis, hyperglycaemia/diabetes mellitus, duration of the disorder, systolic blood pressure, HbA1c, total cholesterol, HDL cholesterol and atrial fibrillation were used to estimate the 10-year risk of coronary heart disease (CHD) in per cent by using the United Kingdom Prospective Diabetes Study (UKPDS) risk calculator. 15 The quality of life changes were measured by using the Euroqol and the SF-36. 16, 17 The Euroqol contains questions about quality of life and a 'thermometer' in which the participants rate their own health. The SF-36 questionnaire covers eight domains of health. The Euroqol thermometer and the SF-36 scales can score from 0 (poorest health) to 100 (optimal health). The score of the Euroqol ranges from 0 (state of dead) to 1 (perfect health). Positive changes after 12 months from the baseline indicate an improvement in quality of life. Current use of medication was measured with a questionnaire.
Sample size calculation and statistical analyses
This trial ought to have sufficient power to detect clinically relevant changes in cardiovascular risk factors within 1 year. The sample size was estimated using a difference in waist circumference of at least 5 cm between the rimonabant and placebo group after 1 year. The SD of waist circumference was, according to the RIO studies, 11 cm. With an 80% power to detect the 5 cm difference (d = 11, a = 0.05, two-tailed, chisquare test, 20% dropout rate), a total group of 190 randomized patients was needed. [7] [8] [9] [10] Intention-to-treat (ITT) analyses were performed. Continuous variables were analysed through one-way analysis of variance. Categorical variables were analysed with the chi-square test. Correction for possible baseline differences was made by using analysis of covariance regression analysis. Data are expressed as mean (±SD), unless indicated otherwise. Statistical analyses were performed using SPSS software version 16.0.
Results
In total, 222 participants (134 male and 88 female) of the original 372 screened subjects were included (Fig. 1) . The main reason for exclusion was not meeting the inclusion criteria, i.e. the combination of an enlarged waist circumference with hyperglycaemia/diabetes. Both groups (placebo and rimonabant) had similar baseline characteristics ( Table 2) . At baseline, the mean age was 59 years (SD 9.0), with a mean body weight of 94 kg and a mean UKPDS risk of CHD in the next 10 years of 16.6% (SD 10.4). Co-medication (antihypertensives, antidiabetics and cholesterol-lowering drugs) was used by 30% of the total population and showed no statistical significant difference between groups.
The 1-year follow-up was completed by 85.6% (n = 190) participants: 90.0% (n = 98) in the placebo group and 81.4% (n = 92) in the rimonabant group (Fig. 1 ). When the European Medicines Agency (EMA) gave negative advice to new prescriptions of rimonabant, only 30 patients were still participating in the study. These patients received an information letter and five of the total participants chose for an earlier follow-up. The others completed their study year as planned, there was no drop out resulting from this news.
The completion rates of the participants, who continued using study medication throughout the whole year, were significantly different, namely 82.6% (n = 90) in the placebo group and 59.3% (n = 67) in the rimonabant group (P < 0.001). Ten patients in the placebo group discontinued participation or the use of study medication because of adverse events versus 30 patients in the rimonabant group (P = 0.001). Only three cases in the rimonabant group were not related to the study medication according to the GP.
Cardiovascular and metabolic risk factors
The ITT analyses were carried out by using the results of the participants who completed the study with study medication and the participants who completed the study, but stopped using the study medication. Lost to follow-up were the participants who stopped both the study and the study medication (n = 32) ( Fig. 1) . Changes in waist circumference, body weight and body mass index (BMI) were significantly greater in the rimonabant group than the placebo group (Table 3) . The changes over time in waist circumference and body weight are shown in separate graphs (Fig. 2) . More than 50% of the effect is visible in the first 3 months. The percentage of patients achieving a 5% or greater loss of their initial body weight was significantly different, namely 45.7% (n = 42) in the rimonabant group compared with 9.2% (n = 9) in the placebo group (P < 0.001).
The other cardiovascular and metabolic risk factors, such as HbA1c, fasting glucose and the lipid parameters (apart from the HDL cholesterol), showed no significant improvement. Triglycerides and diastolic blood pressure deteriorated in the rimonabant group compared with the placebo group. Change in the UKPDS risk of CHD showed no significant differences between the two groups. The estimate of the treatment effect on the main outcome waist circumference did not show any relevant change after correction for the baseline differences in sex, impaired HbA1c status and smoking.
Quality of life
The subjective health of the study population showed statistically significant differences between the rimonabant and the placebo group (Table 4 ). In comparison with the placebo group, the rimonabant group showed deterioration in the EuroQol and two domains of the SF-36: role limitations due to physical health problems and bodily pain.
Discussion
Main findings
This randomized, double-blind, placebo-controlled Phase 4 trial in primary care examined the effectiveness (the effect on cardiovascular risk factors and quality of life) of rimonabant plus lifestyle counselling in daily practice. The 1-year follow-up was completed by 85.6% of the participants from the total group. Rimonabant led to statistically significant greater improvement in waist circumference, body weight and BMI in comparison with the placebo group. Correction for the baseline differences in sex, impaired HbA1c status and smoking was made. The estimate of the treatment did not show any relevant change after this correction. Not only were more kilograms lost, the percentage of participants reaching a 5% loss from initial body weight was also higher in the rimonabant group. Apart from HDL cholesterol changes, there were no further improvements of other cardiovascular risk factors established in the rimonabant group. There was a small statistically significant but clinically irrelevant difference in improved diastolic blood pressure and triglycerides level in favour of the placebo group. Moreover, it is noticeable that the quality of life (illustrating the perceived health of the participant) showed a significant deterioration in the rimonabant group.
The baseline characteristics of the complete study population (the completers plus the lost to follow-up group), compared with the group of completers only, showed no distinct differences. The loss to follow-up and the consequences on the main outcome waist circumference were investigated in both groups (rimonabant and placebo) using a sensitivity analysis. No change, best-case and worst-case scenarios with a maximum effect of -3.64 cm (mean change in waist circumference of the total group completers) were evaluated and still showed significant changes in the rimonabant group.
Strengths and limitations
The strength of this study is that it presents unique Phase 4 results. The CARDIO-REDUSE study aimed to include the primary care cardiometabolic patient, eligible to use this drug, according to the rimonabant leaflet. As a result of this less strict patient selection, this setting seems to better reflect real life circumstances than the clinical Phase 3 trials.
Although a RCT is the best way to assess the effectiveness of a drug, it also has limitations, linked to its design, for extrapolating the results to daily care. Firstly, a placebo-controlled double-blind trial in daily practice remains an artificial situation and can never fully reflect daily care. Secondly, this specific study was intended to be a real life study evaluating the effect of rimonabant in daily practice. In order to measure the effectiveness, the exclusion criteria had to be extended. For example, to measure the effect on CHD risk reduction, patients with clinically significant CVDs were excluded. Additionally, to avoid contamination, patients with known substance abuse, surgical procedures for weight loss, bulimia or anorexia nervosa were also excluded. Thirdly, the duration of exposure to rimonabant was relatively short (12 months) and this period was perhaps inadequate to observe a treatment effect on the overall risk reduction. Ideally, true clinical effectiveness, namely the incidence of CHD, should be measured, but a follow-up period for this long was not realistic. Therefore, longterm effects in daily practice remain uncertain.
Comparison with Phase 3 trials
The results in weight loss were consistent with the RIO trials. 7-10 However, unlike the RIO trials, the CARDIO-REDUSE study showed no significant improvement in other cardiovascular risk factors. Apart from the HDL cholesterol level, all other cholesterol variables did not show significant improvement. These results indicate that rimonabant mainly targets obesity in cardiometabolic patients and showed lower effects than in the controlled research settings.
The fall in quality of life has not been published before in other trials. On the contrary, the RIO diabetes trial reported greater improvement in healthrelated quality of life. At 1 year, the physical function (P = 0.002) and self-esteem domains (P = 0.004) and in the total IWQoL-Lite score (P = 0.006) improved significantly in the rimonabant group. 9 Implications This RCT showed that rimonabant plus lifestyle counselling is less effective in a primary care setting than in controlled research settings. The differences between this Phase 4 trial and the previous Phase 3 trials possibly arise from differences in patient selection and treatment conditions. These results indicate how relevant Phase 4 studies in daily care are. In the past, the terms 'post-marketing surveillance' (PMS) and 'Phase 4 study' have led to confusion and questions about the validity of such trials. 18 Furthermore, the variety of study designs has led to criticism. Not all studies consist of RCTs, some are initiated by pharmaceutical companies, some by regulatory agencies (e.g. Food and Drug Administration or EMA) and some studies are suggested to be initiated to increase familiarity with a drug in order to stimulate prescription in routine medical practice. 18 To date, all anti-obesity drug trials have been limited by their high attrition rate and lack of long-term morbidity and mortality data. 6 The decision to prescribe an anti-obesity drug involves careful assessment of patient's cardiometabolic risk profile and preference, the drug costs, risks and benefits. 19, 20 
Conclusions
Regardless of the recent setbacks with rimonabant, the CARDIO-REDUSE study shows that testing a new drug in real life, shortly after its approval for prescription, is important. This Phase 4 RCT seems to confirm our hypothesis that rimonabant plus lifestyle counselling is less effective in a primary care setting than in controlled research (Phase 3) settings. Therefore, ongoing research in daily practice, namely standardized Phase 4 RCTs, remains relevant to examine the precise impact of future agents. We advise that pharmaceutical companies are requested by the regulatory agencies to perform these trials shortly after approval of a new drug. This seems to be a better approach then requesting PMS activities.
